Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
28 Results for "
M1 phenotype
" in MedChemExpress (MCE) Product Catalog:
Products (28)
28 Results for "M1 phenotype" in MCE Product Catalog:
2
2 Cited Publications
Research Areas:
KPLH1130 is a pyruvate dehydrogenase kinase (PDK) inhibitor. KPLH1130 potently inhibits M1 macrophage polarization by reducing the expression of pro-inflammatory cytokines, decreasing the levels of M1 phenotype markers (HIF-1α, iNOS) and nitric oxide (NO) production. KPLH1130 prevents the reduction of mitochondrial oxygen consumption rate (OCR) induced by inflammatory stimuli (LPS ((HY-D1056) + IFN-γ) in various macrophage types. KPLH1130 improves glucose tolerance in HFD-fed mice. KPLH1130 can be used for the study of obesity-associated metabolic disorders and other inflammatory conditions .
1
1 Cited Publications
Cat. No.: HY-P99364
CAS No.: 1024603-92-6
Synonyms: Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1
1
1 Cited Publications
Cat. No.: HY-W614507
CAS No.: 19132-12-8
Target:
Research Areas:
Dihydronicotinamide riboside is a potent NAD + concentration enhancer. Dihydronicotinamide riboside modulates targets BAX, PUMA, NQO2, and IκB kinase. Dihydronicotinamide riboside mediates apoptosis, induces pro-oxidant activity, mitochondrial dysfunction, metabolic dysregulation, redox modulation, and pro-inflammatory M1 phenotype induction. Dihydronicotinamide riboside increases intracellular and mitochondrial NAD + levels, maintains cell survival against NAD +-depleting genotoxins. Dihydronicotinamide riboside can be used for the research of hepatocellular carcinoma .
1
1 Cited Publications
CSF1R-IN-3 (compound 21) is a potent and orally active CSF-1R inhibitor (IC50=2.1 nM). CSF1R-IN-3 is a potent antiproliferative activity against colorectal cancer cells. CSF1R-IN-3 inhibits the progression of colorectal cancer by suppressing the migration of macrophages, reprograming M2-like macrophages to the M1 phenotype, and enhancing the antitumor immunity .
Cat. No.: HY-P6292A
Target:
Research Areas:
Cat. No.: HY-165099
CAS No.: 158983-53-0
Target:
Research Areas:
C-8 Ceramide-1-phosphate ammonium is a short-chain synthetic C1P analog that inhibits apoptosis and increases cell survival. C-8 Ceramide-1-phosphate ammonium reduces MAPK activation and cytokine expression, induces Ca 2+ mobilization and ERK1/2 phosphorylation, promotes M2-like polarization, and inhibits the M1 phenotype. C-8 Ceramide-1-phosphate ammonium inhibits acidic SMase, stimulates PI3-K/PIP3 generation, and interconverts with ceramide through kinase/phosphatase activity to maintain cellular homeostasis. C-8 Ceramide-1-phosphate ammonium can be used in research related to lipid metabolism and chronic wounds .
Synonyms: AAD-2004
Target:
Prostaglandin Receptor Free Radical Scavengers PGE synthase Reactive Oxygen Species (ROS) Apoptosis
Research Areas:
Crisdesalazine (AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor. Crisdesalazine acts as a potent free radical scavenger that directly neutralizes reactive oxygen species (ROS) including hydrogen peroxide, exerting neuroprotective effects against apoptosis and axonal damage. Crisdesalazine inhibits PGE2 production, mediates inflammatory responses, and promotes the conversion of macrophages from the pro-inflammatory M1 phenotype to the anti-inflammatory M2 phenotype. Crisdesalazine is applicable to neuroprotection research in multiple sclerosis and spinal cord injury .
Target:
Research Areas:
E104 is a selective Toll-like receptor 7 (TLR7) agonist. E104 promotes the release of pro-inflammatory factors and the polarization of macrophages toward the anti-tumor M1 phenotype by activating endosomal TLR7 and triggering downstream NF-κB and IRF signaling pathways. Antibody conjugates of E104 induce tumor regression. E104 can be used in research on pancreatic ductal adenocarcinoma and cancer .
Synonyms: (9S,13R)-12-OPDA
Cat. No.: HY-P11107
CAS No.: 2375823-45-1
Target:
Research Areas:
Cat. No.: HY-118828AS
CAS No.: 2692624-08-9
Synonyms: (9S,13R)-12-OPDA-d5
Target:
Isotope-Labeled Compounds Lipoxygenase PGE synthase Keap1-Nrf2 IKK NF-κB NO Synthase Interleukin Related
Research Areas:
(9S,13R)-12-Oxo phytodienoic acid-d5 ((9S,13R)-12-OPDA-d5) is the deuterated-labeled (9S,13R)-12-Oxo phytodienoic acid (HY-118828A). (9S,13R)-12-Oxo phytodienoic acid ((9S,13R)-12-OPDA) is a mPGES-1 inhibitor and Nrf2 activator. (9S,13R)-12-Oxo phytodienoic acid selectively inhibits mPGES-1 expression and reduces inducible PGE2 production without affecting COX-1 or COX-2. (9S,13R)-12-Oxo phytodienoic acid inhibits the phosphorylation of IKKβ, IκBα, and NF-κB (p65), blocks the nuclear translocation of p65, increases the nuclear translocation of Nrf2, and upregulates HO-1 expression. (9S,13R)-12-Oxo phytodienoic acid inhibits the differentiation of M0 macrophages toward the M1 phenotype and promotes differentiation toward the M2 phenotype. (9S,13R)-12-Oxo phytodienoic acid decreases the levels of NO, PGE2, IL-1β, IL-6, iNOS, and PGD2. (9S,13R)-12-Oxo phytodienoic acid can be used for inflammation research .
Cat. No.: HY-163642
CAS No.: 2379727-88-3
TNF-α agonistic 1 (compound 22a) can repolarize tumor-associated macrophages (TAMs) in the tumor microenvironment (TME) from the M2 phenotype to the M1 anti-tumor phenotype .
Cat. No.: HY-P990061
CAS No.: 2640981-19-5
Synonyms: JTX-8064
Target:
Research Areas:
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antibody and LILRB2 (ILT4) antagonist. Polzastobart specifically binds to and antagonizes LILRB2, relieves ILT4-mediated myeloid immunosuppression, and promotes the polarization of macrophages from an M2-like phenotype to an M1-like phenotype. Polzastobart induces macrophage polarization, IFNγ signaling, and T cell inflammation-related pharmacodynamic responses in ex vivo human renal cancer, lung cancer, and head and neck cancer tissues. Polzastobart can be used in studies related to tumor-associated macrophages and tumor immunity. For the isotype control of Polzastobart, refer to: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
Cat. No.: HY-155762
CAS No.: 2968412-77-1
Research Areas:
Anti-neuroinflammation agent 1 is a potent anti-neuroinflammation agent that regulates polarization BV2 microglia cells from M1 phenotype to M2 phenotype .
Cat. No.: HY-155408
CAS No.: 903639-13-4
Target:
Research Areas:
ALR-27 is an antagonist of the 5-lipoxygenase (5-LOX) activating protein FLAP and has anti-inflammatory activity. ALR-27 potently inhibits 5-LOX product formation (>80%) in pro-inflammatory M1-MDM, with no significant direct inhibition of 5-LOX. ALR-27 not only reduces prostaglandin and leukotriene (LT) production in neutrophils but also increases the production of specialized prolytic mediators in specific human macrophage phenotypes .
Cat. No.: HY-162494
CAS No.: 3044006-76-7
Target:
Research Areas:
PAD4-IN-4 (compound 28) is a potent PAD4 inhibitor (IC50=0.79±0.09 μM). PAD4-IN-4 improves the tumor immune microenvironment by reshaping neutrophil phenotype, upregulating the proportions of dendritic cells and M1 macrophages, and reducing the amount of myeloid-derived suppressor cells. PAD4-IN-4 can be used for Triple-negative breast cancer research .
Cat. No.: HY-169103
Target:
Research Areas:
Neuroprotective agent 5 (compound 28) is a brain permeabilizing agent with anti-neuritis, anti-oxidative damage and neuroprotective effects. Neuroprotective agent 5 exhibits a potent NO inhibitory effect (EC50=0.49 μM), inhibits the release of proinflammatory factors PGE2 and TNF-α, downregulates the expression of iNOS and COX-2 proteins, and promotes the polarization of BV-2 cells from the proinflammatory M1 phenotype to the anti-inflammatory M2 phenotype. In addition, Neuroprotective agent 5 can also inhibit acetylcholinesterase (AChE) activity and Aβ42 aggregation in a dose-dependent manner. Neuroprotective agent 5 can be used for the study of Alzheimer's disease .
Cat. No.: HY-162415
CAS No.: 2760585-35-9
CSF1R-IN-22 (Compound C19) is an orally effective CSF-1R selective inhibitor (IC50<6 nM). CSF1R-IN-22 enhances the secretion of CXCL9 from M2 macrophages, increases CD8 + T cell infiltration. CSF1R-IN-22 boosts anti-tumor immune responses of anti-PD-1, and induces apoptosis in tumor cells. CSF1R-IN-22 can effectively reprogram M2-like TAMs (tumor-associated macrophages) to the M1 phenotype and reshape the TME by inducing the recruitment of CD8 + T cells into tumors and reducing the infiltration of immunosuppressive Tregs and MDSCs .
Cat. No.: HY-184203
SM-06-09 is a potent, highly selective, orally active tetrazolone-based HDAC6 inhibitor with an IC50 value of 0.49 nM. SM-06-09 promotes tumor-associated macrophage (TAM) polarization toward an antitumor M1-like phenotype and enhances macrophage phagocytosis, antigen presentation, and T-cell activation. SM-06-09 remodels the tumor immune microenvironment, exhibits antitumor activity in melanoma models, and enhances the efficacy of anti-PD-1 immune checkpoint blockade .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
